Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 10/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.31 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5718374 | 0.95 | CXCR2 (0.34) | CXCR2CYP2C9NSD2NR3C1PGR | |
| SCHEMBL1360673 | 0.83 | KMT2A (0.32) | CXCR2CYP2C9 | |
| SCHEMBL1561187 | 0.82 | NR3C1 (0.34) | CXCR2CYP2C9NSD2NR3C1PGR | |
| SCHEMBL5718466 | 0.82 | NR3C1 (0.34) | CXCR2CYP2C9NSD2NR3C1PGR | |
| SCHEMBL2866617 | 0.82 | NR3C1 (0.34) | CXCR2CYP2C9NSD2NR3C1PGR | |
| Bromide SCHEMBL4625572 | 0.81 | CXCR2 (0.34) | CXCR2CYP2C9NSD2NR3C1PGR | |
| SCHEMBL1363413 | 0.78 | SLC6A4 (0.36) | CYP2C9SLC6A4 | |
| SCHEMBL1363412 | 0.78 | SLC6A4 (0.36) | CYP2C9SLC6A4 | |
| SCHEMBL1361410 | 0.78 | NSD2 (0.31) | CXCR2CYP2C9NSD2TBXA2RSLC6A4 | |
| Benzoic Acid SCHEMBL1360672 | 0.73 | MRGPRX4 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067640-B2 | Method for the separation of intermediates which may be used for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2011-11-29 | — | — | US | disclosed |
| US-20110065937-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2011-03-17 | — | — | US | disclosed |
| US-20070129561-A1 | Method for the separation of intermediates which may be used for the preparation of escitalopram | H. LUNDBECK A/S (DK) | 2007-06-07 | — | — | US | disclosed |
| EP-1716108-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. Lundbeck A/S (DK) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005077891-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2005-08-25 | — | — | WO | disclosed |
| EP-1534654-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2005-06-01 | — | — | EP | disclosed |
| WO-2004014821-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | H. LUNDBECK A/S (DK) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065937-A1 | METHOD FOR THE SEPARATION OF INTERMEDIATES WHICH MAY BE USED FOR THE PREPARATION OF ESCITALOPRAM | MAOB, HSD17B14, MAOA | CXCR2 3901/4885CYP2C9 29/4885NSD2 1001/4885 |
| US-20070129561-A1 | Method for the separation of intermediates which may be used for the preparation of escitalopram | MAOB, HSD17B14, MAOA | CXCR2 3901/4885CYP2C9 29/4885NSD2 1001/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.